We explore the immense potential of gamma delta T cells, and the challenges in sourcing and scaling up sufficient volumes to ...

Gamma delta (γδ) T cells hold significant potential for unmet medical needs. Yet they are more challenging to source than other T cells, representing as little as 1% to 5% of the total CD3+ T ...

IND clearance paves the way for Acepodia to enter the clinic for the first time with its autoimmune program ACE1831 is an allogeneic gamma delta T cell therapy candidate targeting CD20-expressing ...

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for ...

This strategic realignment enhances our capacity to deliver on the potential of gamma-delta T cell therapies, which are ...

Plenary Oral Presentation at SNO will provide latest clinical trial results from the previously enrolled INB-200 studies of autologous gamma-delta T cells for newly diagnosed glioblastoma (GBM) ...

targeting metastatic clear cell renal cell carcinoma, marking a significant step in utilizing gamma delta CAR T cell therapies for solid tumors. The company also began dosing a lupus nephritis patient ...